Sonnet BioTherapeutics (SONN)
(Delayed Data from NSDQ)
$3.73 USD
-0.48 (-11.40%)
Updated Nov 6, 2024 03:59 PM ET
After-Market: $3.55 -0.18 (-4.83%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.73 USD
-0.48 (-11.40%)
Updated Nov 6, 2024 03:59 PM ET
After-Market: $3.55 -0.18 (-4.83%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study
by Zacks Equity Research
Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer.
Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More
by Zacks Equity Research
Regulatory updates from Galecto (GLTO) and Sonnet BioTherapeutics Holdings (SONN) are in focus in the biotech sector.
Beat the Market the Zacks Way: Vertiv, Costco, Sonnet BioTherapeutics in Focus
by Zacks Equity Research
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Company News for Sep 1, 2021
by Zacks Equity Research
Companies in the news are: NTES, SONN, EGRX, ZEV